| Title: | Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy |
|---|
| Authors: | ID Vrankar, Martina (Author)
ID Kern, Izidor, Klinika Golnik (Author)
ID Stanič, Karmen (Author) |
|---|
| Files: |  PDF - Presentation file, download (822,12 KB)
MD5: 32B12D04B07A172A730190F4FA21CDBD
 URL - Source URL, visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594267/pdf/13014_2020_Article_1696.pdf
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
|---|
| Abstract: | Background: Expression of PD-L1 is the most investigated predictor of benefit from immune checkpoint blockade in advanced NSCLC but little is known about the association of PD-L1 expression and clinicopathological parameters of patients with unresectable stage III NSCLC. Methods: National registry data was searched for medical records of consecutive inoperable stage III NSCLC patients treated with ChT and RT from January 2012 to December 2017. Totally 249 patients were identified that met inclusion criteria and of those 117 patients had sufficient tissue for PD-L1 immunohistochemical staining. Results: Eighty patients (68.4%) expressed PD-L1 of >- 1% and 29.9% of more than 50%. Median PFS was 15.9 months in PD-L1 negative patients and 16.1 months in patients with PD-L1 expression >- 1% (p = 0.696). Median OS in PD-L1 negative patients was 29.9 months compared to 28.5 months in patients with PD-L1 expression >- (p = 0.888). There was no difference in median OS in patients with high PD-L1 expression (>- 50%) with 29.8 months compared to 29.9 months in those with low (1-49%) or no PD-L1 expression (p = 0.694). We found that patients who received a total dose of 60 Gy or more had significantly better median OS (32 months vs. 17.5 months, p < 0.001) as well as patients with PS 0 (33.2 vs. 20.3 months, p = 0.005). Conclusions: In our patients PD-L1 expression had no prognostic value regarding PFS and OS. Patients with good performance status and those who received a total radiation dose of more than 60 Gy had significantly better mOS. |
|---|
| Keywords: | non small cell lung cancer, chemoradiotherapy, stage III |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Place of publishing: | Velika Britanija |
|---|
| Publisher: | Springer Nature |
|---|
| Year of publishing: | 2020 |
|---|
| Number of pages: | str. 1-12 |
|---|
| Numbering: | Vol. 15, no. 1 |
|---|
| PID: | 20.500.12556/DiRROS-12619  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1748-717X |
|---|
| DOI: | 10.1186/s13014-020-01696-z |
|---|
| COBISS.SI-ID: | 35740931 |
|---|
| Copyright: | © The Author(s) 2020. |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 5. 11. 2020;
Članek št. 247;
|
|---|
| Publication date in DiRROS: | 09.11.2020 |
|---|
| Views: | 1406 |
|---|
| Downloads: | 1006 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
